Skip to content
Search

Latest Stories

Drug tariff to go fully paperless from April

Drug tariff will no longer be printed and distributed by the NHS Business Services Authority (NHSBSA) from April 2021 as the system is on its way to make it go fully paperless.

The preface section of the November 2020 drug tariff has been updated to reflect that March 2021 will be the final month in which a printed Drug Tariff will be circulated to community pharmacies.


“From January 2021, where pharmacy contractors have a registered email address with the NHSBSA, a link to the PDF copy will be supplied to that email address each month,” the Pharmaceutical Services Negotiating Committee (PSNC) has said in an update on Wednesday (October 28).

“If any issues arise in receiving a link to the PDF version of the drug tariff at the registered email address, pharmacy teams can contact NHSBSA at nhsbsa.drugtariff@nhs.net.

“This email address can also be used by pharmacy teams to request addition of an email address to the circulation list. Pharmacy teams should note that this mailbox will not be monitored until January 2021”.

Digital formats (an electronic and PDF version) of the drug tariff will continue to be available via the NHSBSA website three working days before the first day of the each month.

The PDF format of the drug tariff is a duplicate of the printed drug tariff which can be downloaded and used offline on a smartphone or tablet device.

Pharmacy teams not currently using the PDF version should familiarise themselves with this format ahead of the move to digital only versions.

PSNC has advised downloading a PDF copy each month to ensure that it can be easily accessed and recommend using the search function (Ctrl+F) to locate any specific information contained in the drug tariff.

The electronic drug tariff is different to the PDF version as it has no page numbers and requires a continuous connection to the internet. Any reference to page numbers in the electronic tariff should be cross-referenced with the PDF version.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less